Literature DB >> 3783274

Hepatic angiosarcoma: mimicking of angioma on three-phase technetium-99m red blood cell scintigraphy.

F Ginsberg, J D Slavin, R P Spencer.   

Abstract

A [99mTc]RBC study in a 63-yr-old man showed intrahepatic lesions which initially had less activity than surrounding liver tissue. When viewed 3 hr later, these had "reversed" and the lesions revealed increased uptake of the radiolabeled red cells. Some extrahepatic areas showed the same pattern (these were in the mesentery of the small bowel). The lesions proved to be angiosarcomas. Hence, the behavior of labeled red cells in these angiosarcomas mimicked that in benign hemangiomas.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783274

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

Review 1.  Angiosarcoma: clinical and imaging features from head to toe.

Authors:  Ayman H Gaballah; Corey T Jensen; Sarah Palmquist; Perry J Pickhardt; Alper Duran; Gregory Broering; Khaled M Elsayes
Journal:  Br J Radiol       Date:  2017-05-04       Impact factor: 3.039

2.  Primary hepatic angiosarcoma: multi-institutional comprehensive cancer centre review of multiphasic CT and MR imaging in 35 patients.

Authors:  Perry J Pickhardt; Douglas Kitchin; Meghan G Lubner; Dhakshina M Ganeshan; Sanjeev Bhalla; Anne M Covey
Journal:  Eur Radiol       Date:  2014-10-04       Impact factor: 5.315

3.  Investigation of focal hepatic lesions: is tomographic red blood cell imaging useful?

Authors:  D C Farlow; P R Chapman; S M Gruenewald; V F Antico; G C Farrell; J M Little
Journal:  World J Surg       Date:  1990 Jul-Aug       Impact factor: 3.352

4.  Primary tumors of the liver.

Authors:  B B Anderson; F Ukah; A Tette; S G Villaflor; D Koh; P Seton
Journal:  J Natl Med Assoc       Date:  1992-02       Impact factor: 1.798

5.  Clinical manifestations of primary hepatic angiosarcoma.

Authors:  Enrique Molina; Alfredo Hernandez
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.